User menu

Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?

Bibliographic reference Hermans, Cédric ; Astermark, J. ; De Moerloose, P.. Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?. In: Journal of Thrombosis and Haemostasis, Vol. 10, no.10, p. 2194-6 (2012)
Permanent URL http://hdl.handle.net/2078/124944
  1. van der Bom Johanna G., Epidemiology of Inhibitors, Current and Future Issues in Hemophilia Care ISBN:9781119979401 p.60-67, 10.1002/9781119979401.ch13
  2. Hay C. R. M., Palmer B., Chalmers E., Liesner R., Maclean R., Rangarajan S., Williams M., Collins P. W., , Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom, 10.1182/blood-2010-09-308668
  3. Lusher Jeanne M., Arkin Steven, Abildgaard Charles F., Schwartz Richard S., Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of Inhibitors, 10.1056/nejm199302183280701
  4. McMillan, Blood, 71, 344 (1988)
  5. Bray, Blood, 83, 2428 (1994)
  6. Gouw Samantha, van den Berg H. Marÿke, The Multifactorial Etiology of Inhibitor Development in Hemophilia: Genetics and Environment, 10.1055/s-0029-1245105
  7. ASTERMARK J., Inhibitor development: patient-determined risk factors : RISK FACTORS FOR INHIBITOR DEVELOPMENT, 10.1111/j.1365-2516.2008.01923.x
  8. ASTERMARK J., ALTISENT C., BATOROVA A., DINIZ M. J., GRINGERI A., HOLME P. A., KARAFOULIDOU A., LOPEZ-FERNÁNDEZ M. F., REIPERT B. M., ROCINO A., SCHIAVONI M., Von DEPKA M., WINDYGA J., FIJNVANDRAAT K., , Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report : NON-GENETIC RISK FACTORS FOR INHIBITOR FORMATION, 10.1111/j.1365-2516.2010.02231.x
  9. PAVLOVA A., DELEV D., LACROIX-DESMAZES S., SCHWAAB R., MENDE M., FIMMERS R., ASTERMARK J., OLDENBURG J., Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-α and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A, 10.1111/j.1538-7836.2009.03636.x
  10. Viel Kevin R., Ameri Afshin, Abshire Thomas C., Iyer Rathi V., Watts Raymond G., Lutcher Charles, Channell Cynthia, Cole Shelley A., Fernstrom Karl M., Nakaya Shelley, Kasper Carol K., Thompson Arthur R., Almasy Laura, Howard Tom E., Inhibitors of Factor VIII in Black Patients with Hemophilia, 10.1056/nejmoa075760
  11. REIPERT B. M., ALLACHER P., HAUSL C., PORDES A. G., AHMAD R. U., LANG I., ILAS J., WINDYGA J., KLUKOWSKA A., MUCHITSCH E. M., SCHWARZ H. P., Modulation of factor VIII-specific memory B cells : MODULATION OF FVIII-SPECIFIC MEMORY B CELLS, 10.1111/j.1365-2516.2008.01962.x
  12. Navarrete A.-M., Dasgupta S., Teyssandier M., Repesse Y., Delignat S., Andre S., Bayry J., Kaveri S. V., Lacroix-Desmazes S., Endocytic receptor for pro-coagulant factor VIII: Relevance to inhibitor formation : , 10.1160/th10-05-0294
  13. KEMPTON C. L., SOUCIE J. M., MILLER C. H., HOOPER C., ESCOBAR M. A., COHEN A. J., KEY N. S., THOMPSON A. R., ABSHIRE T. C., In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study : Inhibitors in mild and moderate hemophilia A, 10.1111/j.1538-7836.2010.04013.x
  14. MANCUSO M. E., GRACA L., AUERSWALD G., SANTAGOSTINO E., Haemophilia care in children - benefits of early prophylaxis for inhibitor prevention, 10.1111/j.1365-2516.2008.01947.x
  15. KURNIK K., BIDLINGMAIER C., ENGL W., CHEHADEH H., REIPERT B., AUERSWALD G., New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development : NEW REGIMEN CAN REDUCE INHIBITOR DEVELOPMENT, 10.1111/j.1365-2516.2009.02122.x
  16. KLUKOWSKA A., KOMRSKA V., JANSEN M., LAGUNA P., Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study : INCIDENCE OF FVIII INHIBITORS FOLLOWING OCTANATE® THERAPY, 10.1111/j.1365-2516.2010.02428.x
  17. DE MOERLOOSE P., FISCHER K., LAMBERT T., WINDYGA J., BATOROVA A., LAVIGNE-LISSALDE G., ROCINO A., ASTERMARK J., HERMANS C., Recommendations for assessment, monitoring and follow-up of patients with haemophilia : FOLLOW-UP OF HAEMOPHILIA PATIENTS, 10.1111/j.1365-2516.2011.02671.x